Fig. 1

Kremen2 is upregulated in NSCLC and contributes to the poor prognosis. A Heatmap of differentially expressed genes filtered in the TCGA database of LUAD patients (red points, P < 0.05). B The differential expression of Kremen2 in the raw TCGA RNA-seq data (n = 57, the y-axis is the raw expression data for each sample). C Kremen2 mRNA expression in normal lung tissues, LUSC, and LUAD tissues was analyzed based on the GEPIA profiling datasets (T, tumor tissues; N, normal tissues). D, E Kremen2 mRNA (n = 9) (D) and Kremen2 protein (E) expression levels were detected in normal lung tissues and paired NSCLC tissues (n = 8). F Representative images from IHC staining of Kremen2 in NSCLC (n = 12) and matched adjacent tissues (scale bars: 100 μm). G Kremen2 protein expression in different human normal lung cell lines and NSCLC cell lines. H, I Kaplan–Meier curves of overall survival and first progression survival analysis showing the survival of NSCLC patients with different Kremen2 gene expression levels (HR, hazard ratio)